Mail

UK markets closed

FTSE 100
8,420.26
-18.39(-0.22%)
FTSE 250
20,749.90
-72.94(-0.35%)
AIM
794.02
+1.52(+0.19%)
GBP/EUR
1.1678
+0.0023(+0.20%)
GBP/USD
1.2706
+0.0035(+0.28%)
Bitcoin GBP
52,534.72
+1,166.43(+2.27%)

9 houses with great-looking gardens

Check out these homes if inspiring outside space tops your property wish list

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Delayed price. Currency in JPY

Add to watchlist

4,130.00

-8.00

(-0.19%)

At close: 03:15PM JST

Currency in JPY

Valuation measures⁴

Market cap (intra-day)	6.49T
Enterprise value	10.86T
Trailing P/E	45.39
Forward P/E	1.43k
PEG ratio (5-yr expected)	52.30
Price/sales (ttm)	1.53
Price/book (mrq)	0.89
Enterprise value/revenue	2.55
Enterprise value/EBITDA	10.86

Trading information

Stock price history

Beta (5Y monthly)	0.54
52-week change ³	-7.43%
S&P500 52-week change ³	26.36%
52-week high ³	4,873.00
52-week low ³	3,900.00
50-day moving average ³	4,195.80
200-day moving average ³	4,303.12

Share statistics

Avg vol (3-month) ³	4.27M
Avg vol (10-day) ³	4.66M
Shares outstanding ⁵	1.57B
Implied shares outstanding ⁶	1.57B
Float ⁸	1.55B
% held by insiders ¹	0.03%
% held by institutions ¹	44.96%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	196
Forward annual dividend yield ⁴	4.74%
Trailing annual dividend rate ³	188.00
Trailing annual dividend yield ³	4.54%
5-year average dividend yield ⁴	4.68
Payout ratio ⁴	206.23%
Dividend date ³	N/A
Ex-dividend date ⁴	27 Sept 2024
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Mar 2024
Most-recent quarter (mrq)	31 Mar 2024

Profitability

Profit margin	3.38%
Operating margin (ttm)	-7.40%

Management effectiveness

Return on assets (ttm)	1.57%
Return on equity (ttm)	2.12%

Income statement

Revenue (ttm)	4.26T
Revenue per share (ttm)	2,725.41
Quarterly revenue growth (yoy)	9.90%
Gross profit (ttm)	N/A
EBITDA	1.09T
Net income avi to common (ttm)	144.07B
Diluted EPS (ttm)	90.86
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	457.8B
Total cash per share (mrq)	291.78
Total debt (mrq)	5.53T
Total debt/equity (mrq)	76.05%
Current ratio (mrq)	1.11
Book value per share (mrq)	4,635.56

Cash flow statement

Operating cash flow (ttm)	716.34B
Levered free cash flow (ttm)	35.08B